Amedeo Smart

Free Medical Literature Service

 

Amedeo

Leukemia
  Free Subscription

Articles published in
Biochem Pharmacol
    March 2024
  1. DI GIORGIO C, Morretta E, Lupia A, Bellini R, et al
    Bile acids serve as endogenous antagonists of the Leukemia inhibitory factor (LIF) receptor in oncogenesis.
    Biochem Pharmacol. 2024;223:116134.
    >> Share

    February 2024
  2. HURRISH KH, Su Y, Patel S, Ramage CL, et al
    Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro.
    Biochem Pharmacol. 2024;220:115981.
    >> Share

    November 2023
  3. CHIOU JT, Lee YC, Chang LS
    Hydroquinone-selected chronic myelogenous leukemia cells are sensitive to chloroquine-induced cytotoxicity via MCL1 suppression and glycolysis inhibition.
    Biochem Pharmacol. 2023 Nov 19:115934. doi: 10.1016/j.bcp.2023.115934.
    >> Share

    October 2023
  4. HAN H, Zhao C, Liu M, Zhu H, et al
    Mitochondrial complex I inhibition by homoharringtonine: A novel strategy for suppression of chronic myeloid leukemia.
    Biochem Pharmacol. 2023 Oct 21:115875. doi: 10.1016/j.bcp.2023.115875.
    >> Share

    September 2023
  5. OIKONOMOU A, Valsecchi L, Quadri M, Watrin T, et al
    High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia.
    Biochem Pharmacol. 2023 Sep 15:115809. doi: 10.1016/j.bcp.2023.115809.
    >> Share

    August 2023
  6. CARTER JL, Su Y, Qiao X, Zhao J, et al
    Acquired Resistance to Venetoclax plus Azacitidine in Acute Myeloid Leukemia: in vitro Models and Mechanisms.
    Biochem Pharmacol. 2023 Aug 19:115759. doi: 10.1016/j.bcp.2023.115759.
    >> Share

  7. CHIOU JT, Wu YY, Lee YC, Chang LS, et al
    BCL2L1 inhibitor A-1331852 inhibits MCL1 transcription and triggers apoptosis in acute myeloid leukemia cells.
    Biochem Pharmacol. 2023;215:115738.
    >> Share

    July 2023
  8. TOSIC N, Marjanovic I, Lazic J
    Pediatric acute myeloid leukemia: insight into genetic landscape and novel targeted approaches.
    Biochem Pharmacol. 2023 Jul 31:115705. doi: 10.1016/j.bcp.2023.115705.
    >> Share

  9. ABDEL-AZIZ AK
    Advances in acute myeloid leukemia differentiation therapy: A critical review.
    Biochem Pharmacol. 2023;215:115709.
    >> Share

  10. FRANZA M, Albanesi J, Mancini B, Pennisi R, et al
    The clinically relevant CHK1 inhibitor MK-8776 induces the degradation of the oncogenic protein PML-RARalpha and overcomes ATRA resistance in acute promyelocytic leukemia cells.
    Biochem Pharmacol. 2023 Jul 3:115675. doi: 10.1016/j.bcp.2023.115675.
    >> Share

  11. AL-ANTARY ET, Gupte A, Carter J, Kaafarani M, et al
    Curing childhood cancer the "Natural" Way: Nature as the source of chemotherapy agents.
    Biochem Pharmacol. 2023;213:115630.
    >> Share

    May 2023
  12. HE C, Peng Z, Zhang D, Guo Y, et al
    Sunitinib selectively targets leukemogenic signaling of mutant SHP2 in juvenile myelomonocytic leukemia.
    Biochem Pharmacol. 2023;213:115588.
    >> Share

    April 2023
  13. LI Q, Wang M, Liu L
    The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia.
    Biochem Pharmacol. 2023 Apr 4:115539. doi: 10.1016/j.bcp.2023.115539.
    >> Share

  14. ZHANG Y, Sultonova RD, You SH, Choi Y, et al
    The anticancer effect of PASylated calreticulin-targeting L-ASNase in solid tumor bearing mice with immunogenic cell death-inducing chemotherapy.
    Biochem Pharmacol. 2023;210:115473.
    >> Share

  15. OU ZY, Wang K, Shen WW, Deng G, et al
    Oncogenic FLT3 internal tandem duplication activates E2F1 to regulate purine metabolism in acute myeloid leukaemia.
    Biochem Pharmacol. 2023;210:115458.
    >> Share

    March 2023
  16. CHIOU JT, Hsu CC, Hong YC, Lee YC, et al
    Cytarabine-induced destabilization of MCL1 mRNA and protein triggers apoptosis in leukemia cells.
    Biochem Pharmacol. 2023 Mar 14:115494. doi: 10.1016/j.bcp.2023.115494.
    >> Share

    January 2023
  17. LEE YC, Chiou JT, Chang LS
    AMPK inhibition induces MCL1 mRNA destabilization via the p38 MAPK/miR-22/HuR axis in chronic myeloid leukemia cells.
    Biochem Pharmacol. 2023 Jan 28:115442. doi: 10.1016/j.bcp.2023.115442.
    >> Share

    October 2022
  18. HEGE HURRISH K, Qiao X, Li X, Su Y, et al
    Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia.
    Biochem Pharmacol. 2022;205:115283.
    >> Share

    June 2022
  19. GUO J, Liu K, Wang J, Jiang H, et al
    A rational foundation for micheliolide-based combination strategy by targeting redox and metabolic circuit in cancer cells.
    Biochem Pharmacol. 2022;200:115037.
    >> Share

    April 2022
  20. GUPTE A, Al-Antary ET, Edwards H, Ravindranath Y, et al
    The Paradox of Myeloid Leukemia Associated with Down Syndrome.
    Biochem Pharmacol. 2022 Apr 25:115046. doi: 10.1016/j.bcp.2022.115046.
    >> Share

  21. ZHANG H, Song T, Wang Z, Laura Bonnette U, et al
    Bcr-Abl drives the formation of Hsp70/Bim PPI to stabilize oncogenic clients and prevent cells from undergoing apoptosis.
    Biochem Pharmacol. 2022;198:114964.
    >> Share

    March 2022
  22. LEE YC, Chiou JT, Wang LJ, Chang LS, et al
    Hydroquinone destabilizes BIM mRNA through upregulation of p62 in chronic myeloid leukemia cells.
    Biochem Pharmacol. 2022;199:115017.
    >> Share

  23. SUN L, Wang J, Wang Q, He Z, et al
    Pretreatment of umbilical cord derived MSCs with IFN-gamma and TNF-alpha enhances the tumor-suppressive effect on acute myeloid leukemia.
    Biochem Pharmacol. 2022;199:115007.
    >> Share

    February 2022
  24. XING GAO Z, Long Cui Z, Ran Zhou M, Fu Y, et al
    The new mitochondrial uncoupler BAM15 induces ROS production for treatment of acute myeloid leukemia.
    Biochem Pharmacol. 2022 Feb 19:114948. doi: 10.1016/j.bcp.2022.114948.
    >> Share

  25. XIN Q, Chen Z, Wei W, Wu Y, et al
    Animal Models of Acute lymphoblastic leukemia: recapitulating the human disease to evaluate drug efficacy and discover therapeutic targets.
    Biochem Pharmacol. 2022 Feb 17:114970. doi: 10.1016/j.bcp.2022.114970.
    >> Share

    October 2021
  26. VIGON L, Martinez-Roman P, Rodriguez-Mora S, Torres M, et al
    Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy.
    Biochem Pharmacol. 2021;192:114666.
    >> Share

    July 2021
  27. LU X, Yan G, Dawood M, Klauck SM, et al
    A novel moniliformin derivative as pan-inhibitor of histone deacetylases triggering apoptosis of leukemia cells.
    Biochem Pharmacol. 2021 Jul 12:114677. doi: 10.1016/j.bcp.2021.114677.
    >> Share

    June 2021
  28. KIM JH, Lee SJ, Kang KW, Lee BH, et al
    CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells.
    Biochem Pharmacol. 2021;190:114658.
    >> Share

    April 2021
  29. WANG F, Huang J, Guo T, Zheng Y, et al
    Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
    Biochem Pharmacol. 2021 Apr 5:114538. doi: 10.1016/j.bcp.2021.114538.
    >> Share

  30. CHIOU JT, Lee YC, Huang CH, Wang LJ, et al
    Inhibition of Sp1-mediated survivin and MCL1 expression cooperates with SLC35F2 and myeloperoxidase to modulate YM155 cytotoxicity to human leukemia cells.
    Biochem Pharmacol. 2021 Apr 5:114544. doi: 10.1016/j.bcp.2021.114544.
    >> Share

    January 2021
  31. MARENSI V, Keeshan KR, MacEwan DJ
    Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors.
    Biochem Pharmacol. 2021;183:114348.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016